These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 7248992)

  • 21. Melanoma and chemotherapy.
    Aust JB
    Prog Clin Cancer; 1975; 6():199-204. PubMed ID: 53859
    [No Abstract]   [Full Text] [Related]  

  • 22. [Current trends in chemotherapy of the upper aerodigestive system].
    Chauvergne J
    Rev Laryngol Otol Rhinol (Bord); 1983; 104(2):199-206. PubMed ID: 6878920
    [No Abstract]   [Full Text] [Related]  

  • 23. Where are we going with regional therapy for melanoma?
    Tyler D
    Ann Surg Oncol; 2004 May; 11(5):455-7. PubMed ID: 15078631
    [No Abstract]   [Full Text] [Related]  

  • 24. Cutaneous melanoma: available therapy for metastatic disease.
    Tarhini AA; Agarwala SS
    Dermatol Ther; 2006; 19(1):19-25. PubMed ID: 16405566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemotherapy for metastatic melanoma: time for a change?
    Gogas HJ; Kirkwood JM; Sondak VK
    Cancer; 2007 Feb; 109(3):455-64. PubMed ID: 17200963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma.
    Garbe C
    Melanoma Res; 1993 Aug; 3(4):291-9. PubMed ID: 7693093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dacarbazine DTIC and carboplatin as an outpatient treatment for disseminated malignant melanoma.
    Nieboer P; Mulder NH; Van Der Graaf WT; Willemse PH; Hospers GA
    Anticancer Res; 2001; 21(4B):3115-6. PubMed ID: 11712820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Care of the patient undergoing interferon therapy.
    Garvey EC; Matutat RJ; Bolten D
    Cancer Nurs; 1983 Aug; 6(4):303-6. PubMed ID: 6192903
    [No Abstract]   [Full Text] [Related]  

  • 29. Is there any reason to delay introduction of tumor necrosis factor in the management of in-transit metastasis of unresectable melanoma?
    Garrido-Laguna I; Ponz M; Espinós J
    J Clin Oncol; 2007 Mar; 25(9):1149; author reply 1149-51. PubMed ID: 17369585
    [No Abstract]   [Full Text] [Related]  

  • 30. [Nausea and vomiting in cytostatic therapy of melanoma patients with the use of metoclopramide and corticosteroid or ondansetron].
    Czeglédi F; Baki M
    Orv Hetil; 1994 Oct; 135(44):2415-9. PubMed ID: 7970661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
    Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
    Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biochemotherapy for melanoma: rational therapeutics in the search for weapons of melanoma destruction.
    Margolin KA
    Cancer; 2004 Aug; 101(3):435-8. PubMed ID: 15274056
    [No Abstract]   [Full Text] [Related]  

  • 33. Randomized trials in melanoma: an update.
    Eggermont AM
    Surg Oncol Clin N Am; 2006 Apr; 15(2):439-51. PubMed ID: 16632225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemic therapy of disseminated malignant melanoma: an evidence-based overview of the state-of-the-art in daily routine.
    Nashan D; Müller ML; Grabbe S; Wustlich S; Enk A
    J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1305-18. PubMed ID: 17958834
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
    Tourani JM; Pfister C; Tubiana N; Ouldkaci M; Prevot G; Lucas V; Oudard S; Malet M; Cottu P; Ferrero JM; Mayeur D; Rixe O; Sun XS; Bernard O; Andre T; Tournigand C; Muracciole X; Guilhot J;
    J Clin Oncol; 2003 Nov; 21(21):3987-94. PubMed ID: 14581421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?
    Schuchter LM
    J Clin Oncol; 2004 Jan; 22(1):7-10. PubMed ID: 14665612
    [No Abstract]   [Full Text] [Related]  

  • 37. [To outwit melanoma with its own tricks].
    Bischoff A
    MMW Fortschr Med; 2003 Apr; 145(15):4-6, 8, 10. PubMed ID: 15104255
    [No Abstract]   [Full Text] [Related]  

  • 38. Lack of antitumour activity of human recombinant tumour necrosis factor-alpha, alone or in combination with melphalan in a nude mouse human melanoma xenograft system.
    Furrer M; Altermatt HJ; Ris HB; Althaus U; Rüegg C; Liénard D; Lejeune FJ
    Melanoma Res; 1997 Aug; 7 Suppl 2():S43-9. PubMed ID: 9578416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isolated limb perfusion: past experience and present studies using a minimal-access approach.
    Rosin DR
    Melanoma Res; 1994 Mar; 4 Suppl 1():51-5. PubMed ID: 8038598
    [No Abstract]   [Full Text] [Related]  

  • 40. [Aranoza -- a new Russian antineoplastic drug].
    Gorbunova VA; Orel NF; Semina OV; Egorov GN; Borodkina AG; Manziuk LV
    Vopr Onkol; 2001; 47(6):672-5. PubMed ID: 11826486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.